Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy
Article Abstract:
About 10% of HIV patients who take highly active antiretroviral therapy (HAART) will develop liver damage from the drugs, according to a study of 222 HIV patients. The highest risk occurs in those with co-existing hepatitis C, those who use alcohol, and older patients.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients
Article Abstract:
A study is carried out to assess whether the early monitoring of ribavirin(RBV) plasma levels could help to predict anemia as well as early hepatitis C virus (HCV) RNA response in HIV/HCV-coinfected individuals. It is found that the RBV levels correlate with the development of anemia and with the achievement of an early virologic response.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Severe liver disease associated with prolonged exposure to antiretroviral drugs
Article Abstract:
Cryptogenic liver disease (CLD) is defined as persistently elevated aminotransferases levels in the absence of Hepatitis C and/or B viruses replication and of other common causes of liver disease. An analysis concluded that CLD is an uncommon condition in HIV-positive individuals and might be associated with prolonged didanosine.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors
- Abstracts: Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV-1 infected patients
- Abstracts: Elevations of group II phospholipase A(sub 2) concentrations in serum and amniotic fluid in association with preterm labor
- Abstracts: Amniotic fluid concentrations of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during pregnancy and labor
- Abstracts: The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV- 1- infected patients